Microcirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies

被引:90
|
作者
de Kort, H. [1 ]
Willicombe, M. [2 ]
Brookes, P. [3 ]
Dominy, K. M. [1 ]
Santos-Nunez, E. [3 ]
Galliford, J. W. [2 ]
Chan, K. [2 ]
Taube, D. [2 ]
McLean, A. G. [2 ]
Cook, H. T. [1 ]
Roufosse, C. [1 ]
机构
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Histopathol, London, England
[2] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Imperial Coll Kidney & Transplant Ctr, London, England
[3] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Histocompatibil & Immunogenet Lab, London, England
关键词
Antibody-mediated rejection; C4d; donor-specific antibodies; histopathology; microcirculation inflammation; renal transplantation; ACUTE HUMORAL REJECTION; HLA ANTIBODIES; KIDNEY-TRANSPLANT; MEDIATED REJECTION; ALLOGRAFT PATHOLOGY; GRAFT FAILURE; RECIPIENTS; CLASSIFICATION; BIOPSIES;
D O I
10.1111/j.1600-6143.2012.04325.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
In renal transplant patients with de novo donor-specific antibodies (dnDSA) we studied the value of microcirculation inflammation (MI; defined by the addition of glomerulitis (g) and peritubular capillaritis (ptc) scores) to assess long-term graft survival in a retrospective cohort study. Out of all transplant patients with standard immunological risk (n = 638), 79 (12.4%) developed dnDSA and 58/79 (73%) had an indication biopsy at or after dnDSA development. Based on the MI score on that indication biopsy patients were categorized, MI0 (n = 26), MI1?+?2 (n = 21) and MI?=?3 (n = 11). The MI groups did not differ significantly pretransplantation, whereas posttransplantation higher MI scores developed more anti-HLA class I?+?II DSA (p?= 0.011), showed more TCMR (p?<?0.001) and showed a trend to C4d-positive staining (p = 0.059). Four-year graft survival estimates from time of indication biopsy were MI0 96.1%, MI1?+?2 76.1% and MI?=?3 17.1%; resulting in a 24-fold increased risk of graft failure in the MI?=?3 compared to the MI0 group (p = 0.003; 95% CI [3.0196.0]). When adjusted for C4d, MI?=?3 still had a 21-fold increased risk of graft failure (p = 0.005; 95% CI [2.5180.0]), while C4d positivity on indication biopsy lost significance. In renal transplant patients with de novo DSA, microcirculation inflammation, defined by g?+?ptc, associates with graft survival.
引用
收藏
页码:485 / 492
页数:8
相关论文
共 50 条
  • [31] De Novo Donor-Specific Antibodies After Allograft Nephrectomy
    Lucisano, G.
    Brookes, P.
    Santos-Nunez, E.
    Firmin, N.
    Gunby, N.
    Hassan, S.
    Gueret-Wardle, A.
    Willicombe, M.
    Taube, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 222 - 223
  • [32] The impact of early de novo donor-specific antibodies on lung transplant outcomes: Is timing everything?
    King, Christopher S.
    Cochrane, Adam B.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (09): : 1057 - 1058
  • [33] DE NOVO DONOR-SPECIFIC HLA ANTIBODIES IN LOW RISK PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
    Yilmaz, Alev
    Oguz, Fatma Savran
    Usta, Sebahat
    Yildirim, Zeynep Yuruk
    Pehlivanoglu, Cemile
    Kekik, Cigdem
    Emre, Sevinc
    PEDIATRIC NEPHROLOGY, 2015, 30 (09) : 1724 - 1724
  • [34] Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients
    Razia, Deepika
    Hu, Chengcheng
    Cherrier, Lauren
    Nasar, Aasya
    Walia, Rajat
    Tokman, Sofya
    TRANSPLANT IMMUNOLOGY, 2022, 75
  • [35] PERSISTENT DE NOVO DONOR-SPECIFIC ANTIBODIES ARE ASSOCIATED WITH DECREASED SURVIVAL IN LUNG TRANSPLANT RECIPIENTS
    Kauke, Teresa
    Schmitzer, Magdalena
    Kneidinger, Nikolaus
    Neurohr, Claus
    Schramm, Rene
    Von Dossow, Vera
    Winter, Hauke
    TRANSPLANT INTERNATIONAL, 2017, 30 : 33 - 33
  • [36] DE NOVO DONOR-SPECIFIC HLA ANTIBODIES IN LOW RISK PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
    Yilmaz, A.
    Yildirim, Z. Yuruk
    Pehlivanoglu, C.
    Nayir, A.
    Emre, S.
    Savran, F. Oguz
    Usta, S.
    Kekik, C.
    PEDIATRIC TRANSPLANTATION, 2015, 19 : 125 - 125
  • [37] HLA Donor-Specific Antibodies and Graft Outcome in Pediatric Renal Transplant Recipients.
    Bryan, Christopher F.
    Brewer, Brenda
    Warady, Bradley A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 713 - 714
  • [38] Peritubular Capillary Basement Membrane Multilayering in Renal Allograft Biopsies of Patients With De Novo Donor-Specific Antibodies
    de Kort, Hanneke
    Willicombe, Michelle
    Brookes, Paul
    Moran, Linda B.
    Santos-Nunez, Eva
    Galliford, Jack W.
    Taube, David
    McLean, Adam G.
    Moss, Jill
    Cook, H. Terence
    Roufosse, Candice
    TRANSPLANTATION, 2016, 100 (04) : 889 - 897
  • [39] Human Leukocyte Antigen Compatibility and De Novo Donor-Specific Antibodies in Long-term Renal Transplant Patients With Stable Graft Function
    Kasimatis, E.
    Fylaktou, A.
    Karampatakis, T.
    Schoina, M.
    Zarras, C.
    Anastasiou, A.
    Papachristou, M.
    Boukla, A.
    Daoudaki, M.
    Fouzas, I.
    Papagianni, A.
    TRANSPLANTATION PROCEEDINGS, 2019, 51 (02) : 413 - 415
  • [40] De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation
    Cole, Robert Townsend
    Gandhi, Jonathan
    Bray, Robert A.
    Gebel, Howard M.
    Morris, Alanna
    McCue, Andrew
    Yin, Michael
    Laskar, S. Raja
    Book, Wendy
    Jokhadar, Maan
    Smith, Andrew
    Duc Nguyen
    Vega, J. David
    Gupta, Divya
    CLINICAL TRANSPLANTATION, 2017, 31 (04)